FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Intuitive Surgical Q1: Robust Growth In Revenue, Eps, And Procedures Volumes

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Intuitive Surgical delivered robust Q1 2026 results with non-GAAP EPS of $2.50, beating the $2.11 consensus estimate (+38% Y/Y). Revenue surged to $2.77B (+23% Y/Y), above the $2.6B consensus view, driven by worldwide procedures growing 17% Y/Y with da Vinci procedures up 16% and Ion procedures accelerating 39%. System placements reached 431 da Vinci systems versus 367 in Q1 2025, while da Vinci 5 placements surged to 232 systems from 147, showing strong adoption of the next-generation platform. Management guided worldwide da Vinci procedure growth of 13.5%-15.5% with non-GAAP gross margins expected at 67.5%-68.5%, incorporating an estimated 1.0% revenue impact from current tariffs. The installed base reached 11,395 da Vinci systems (+12% Y/Y), while non-GAAP gross margin expanded to 67.8% from 66.4% and operating income grew 40% Y/Y, demonstrating strong operational leverage with a robust balance sheet of $7.98B in cash.

Related Articles

Asia

Shakti Pumps (India) Invests INR100 Million in EV Mobility Unit

Shakti Pumps (India) (NSE:SHAKTIPUMP, BOM:531431) said it has invested 100 million Indian rupees in its wholly owned subsidiary Shakti EV Mobility by subscribing to 10 million equity shares, according to a Tuesday filing to the Indian stock exchanges.Shares of the company rose 1% in Wednesday's trade.With this, Shakti Pumps' total investment in the EV mobility unit has increased to 650 million Indian rupees, the filing said.The investment is aimed at supporting business expansion of the subsidiary, it added.

$BOM:531431$NSE:SHAKTIPUMP
Asia

Challenger's Fiscal 2026 Q3 Update Missed Consensus Across Key Life Metrics, Jarden Says

Challenger's (ASX:CGF) fiscal 2026 third-quarter update missed consensus across key Life metrics, with FM outflows significantly worse than expected, driven by institutional equity mandate attrition in both Australian and global equities, according to a Tuesday note by Jarden.The firm's redemption of all CGFPC notes on May 25 simplifies the capital structure, reduces the AT1 coupon burden, and is earnings-per-share accretive.Jarden sees balanced risk/reward for Challenger in the future, with catalysts including capital management flexibility from the Australian Prudential Regulation Authority reform, as well as expanding retirement partnerships across superfunds.It lowered its fiscal 2026 sales forecast to reflect weaker institutional fixed-term sales, partially offset by higher retail annuity sales as partnerships come online.The investment firm retained its neutral rating on Challenger and raised the price target to AU$8.70 per share from AU$8.60 per share.

$ASX:CGF
Asia

Proya Cosmetics 2025 Profit Down 4%, Revenue Slips 2%

Proya Cosmetics (SHA:603605) posted 2025 attributable net profit of 1.50 billion yuan, down 3.5% from 1.55 billion yuan the previous year.Earnings per share slid to 3.80 yuan from 3.92 yuan, according to a Wednesday filing with the Shanghai bourse.Operating revenue declined 1.7% year over year to 10.6 billion yuan from 10.8 billion yuan.Shares of the cosmetics maker were up over 1% in recent trade.

$SHA:603605